SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-24-008113
Filing Date
2024-03-01
Accepted
2024-03-01 08:01:39
Documents
16
Period of Report
2024-03-01
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K prme-20240301.htm   iXBRL 8-K 27355
2 EX-99.1 a03-01x2024xpressrelease.htm EX-99.1 59619
6 image.jpg GRAPHIC 8641
  Complete submission text file 0001628280-24-008113.txt   237806

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT prme-20240301.xsd EX-101.SCH 1919
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT prme-20240301_lab.xml EX-101.LAB 24834
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT prme-20240301_pre.xml EX-101.PRE 13055
17 EXTRACTED XBRL INSTANCE DOCUMENT prme-20240301_htm.xml XML 2912
Mailing Address 21 ERIE ST. CAMBRIDGE MA 02139
Business Address 21 ERIE ST. CAMBRIDGE MA 02139 617-465-0013
Prime Medicine, Inc. (Filer) CIK: 0001894562 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41536 | Film No.: 24707021
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)